5 ms·
As someone who works in the industry, you pretty much covered it. If you dose people with a new vaccine, you’ll need to monitor them 6 months at a minimum. 12
by refurb 7y ago
As someone who works in the industry, you pretty much covered it.
If you dose people with a new vaccine, you’ll need to monitor them 6 months at a minimum. 12 months would be better.
It takes 3 months to nail down the protocol and for all the sites to be ready. Then you start recruiting and for a vaccine, you’d want a large population (reflects usage). So assume 6 months to recruit 1000 people. They don’t all start at the same time, so if you’re tracking for 6 months, it will probably take 9 monthsfor the last person to finish the trial.
Then you need to analyze all the data you collected, so another 3 months. Then the FDA takes 3 months to review and approve.
There is a TON of work that goes into running a clinical trial.
- WalterBright 7y agoBut it does sound like if there's priority and fear, much time could be saved. For example, "6 months to recruit 1000 people". I suspect in this case, a week can work. > Then you need to analyze all the data you collected, so another 3 months. Help me understand this. You vaccinate 1000 people. In 6 months, the number of them that get sick is 10% of the rate of the unvaccinated. 0.1% have a bad reaction. How much more analysis do you need? > the FDA takes 3 months to review and approve How much time if that is moved to the front of the queue and all hands work on it? Given how enormously disruptive the coronavirus is, we cannot afford to not have all hands working on it.
- thisiszilff 7y agoNot who you're replying to, but I imagine bad, immediate reactions will be easy to spot, but more subtle, chronic problems would be found only after analysis. A part of this work would be figuring out what is attributable to the vaccine and what is not.
- refurb 7y agoLet's tackle recruitment. I've seen trials recruit really fast and that took a month. It's not like someone says "hey I'd like to take part in this trial" and you give them a shot of drug. You need to screen everyone who comes in. Basic labs, then make sure they don't have some other disease that will mess up the results. That's just one part of it. Then in terms of the trial, 6 months would be nice, but it wouldn't be ethical to actually expose them to the virus. You'd simply need to recruit a very large number of patients and see if the treatment groups has less disease than the non-treated group. With infection rates pretty low across the entire population, you'd need to recruit thousands, just to capture the handful that actually get exposed. Then when it comes to analysis, you need to clean the data (yes, there will be errors), then you need to do a statistical analysis of not only efficacy but every possible side effect. You're probably measuring things like viral shedding, so that's another entire dataset. Oh, then you'll have missing data. Do you toss that patient's data out entirely? Or keep them? What impact does that have on your conclusion? I could go on and on, but suffice to say it's a ton of work. And yes, you can speed up some parts, but other parts you just have to let them run their course.
- dantillberg 7y agoIf tens or hundreds of thousands of people were dying every day from the virus, might we find many volunteers willing to be intentionally exposed to the virus in order to rapidly test the efficacy of a vaccine? I imagine so. I believe the magnitude of this pandemic will in time push us (rather violently) to think outside the box.
- majewsky 7y agoEven if volunteers take the vaccine, this will not significantly change the timeline. Do you really want to cut short the observation time to e.g. 1 month, then greenlight the vaccine and administer it to millions or billions of people, only to find out that after 6 months it causes an aneurysm or whatever in 10% of them?
- refurb 7y agoThat's a key issue. If you're testing a drug for a serious cancer, then there is a lot of tolerance for side effects - the alternative is death, so even if it causes things like nerve damage, it's an acceptable risk. With vaccines, you're going to treat a huge percentage of the population and they'll be healthy when you give it to them. As such, the risk-benefit analysis is much different since there is a chance for serious harm.
- trashtester 7y agoStart by 100 people, monitor for 1 month. If it looks promising, add 1000 people, monitor for 1 month. If it looks promising, add 10000 people, monitor for 1 month. If it looks promising, add 100000 people, monitor for 1 month. If it looks promising, add 1000000 people, monitor for 1 month. And so on. The exact rate could be set according to the actual infection and death rates in the population. Given the current costs of curfew, we could create an entire government agency just to administer this, and still save trillions. For inspiration, consider the Manhatten project.
- ahpearce 7y ago> rapidly test the efficacy of a vaccine How do you test the efficacy if you don't know who you're injecting? Maybe it works really well on a certain population, and reacts harmfully to people with some pre-existing genetic trait or condition. You wouldn't know, because you took a random set of volunteers. If you're going to counter and say "we'd still do the pre-analysis on the volunteers"... Well, that's what takes time.
- URSpider94 7y agoYes, it’s an emergency, but many parts of the process just take as long as they take. Throwing more people and money at the problem can ensure that we have many parallel solutions in the pipeline, but won’t get us there faster.
- patrec 7y agoI don't see why. Can you spell out what's inherently slow apart from the observation phases?
- acchow 7y agoAny chance review and approval can take 3 days instead of 3 months? For example with the review process happening concurrently while monitoring the whole trial?
- refurb 7y agoSure, you could probably accelerate review from 3 months to a few weeks. The FDA is familiar with rolling submissions where you send data to them as it becomes available. 3 days? That's really aggressive.
- mancerayder 7y agoThe OP and this response are both very useful for us to read. This is speculative but what process would you expect them to follow for these next steps of expanding the scope of testing volunteers? Would they prioritize higher-risk people like medical? Older people? Healthy people? Some random combo? Volunteers? There are going to be a lot of volunteers.